Erika Hamilton, Medical Oncologist and the Director of Breast Cancer Program at the Sarah Cannon Research Institute, shared a post on LinkedIn:
“Reshma Mahtani updates us at NOSCM New Orleans Summer Cancer Meeting in early stage HR+ BC.
Takeaways:
- Many are now spared chemotherapy
- Don’t underestimate the benefit of ovarian suppression therapy
- CDK4/6i therapy is an additional tool for higher risk patients
Edgardo S. Santos, MD, FACP, FASCO”
More posts featuring Erika Hamilton on OncoDaily.